Granic Antoneta, Hurst Christopher, Dismore Lorelle, Dodds Richard M, Witham Miles D, Robinson Sian M, Sayer Avan A
AGE Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle upon Tyne, United Kingdom; NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom.
AGE Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle upon Tyne, United Kingdom; NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom.
Mech Ageing Dev. 2023 Jan;209:111744. doi: 10.1016/j.mad.2022.111744. Epub 2022 Nov 8.
Advanced glycation end products (AGEs) and AGEs receptor (RAGE) may play a role in sarcopenia. This systematic review evaluated the associations between AGEs measured in tissues (skin) by autofluorescence (SAF) and/or circulation (blood, urine) and muscle health outcomes (strength, mass, function) and sarcopenia in observational studies.
MEDLINE, Embase, Scopus and Web of Science were searched for studies reporting associations between AGEs and muscle-related outcomes in community-dwelling adults aged ≥ 30 years (until March 2022).
Fourteen cross-sectional and one prospective study were included in the narrative summary. SAF was negatively associated with muscle strength, mass, and physical functioning in adults aged ≥ 30 years (four studies), and muscle mass (three studies), strength, and sarcopenia (one study) in adults aged ≥ 65 years. Circulating AGEs were negatively associated with muscle strength and physical functioning (four studies) and predicted the risk of walking disability (one prospective study), and sarcopenia (one study) in older adults. The role of RAGE in muscle health was inconclusive.
SAF and circulating AGEs were negatively associated with muscle-related outcomes in adults aged ≥ 30 years in cross-sectional studies. This finding should be confirmed in well-designed prospective studies investigating sarcopenia, as AGEs represent a potentially modifiable target for intervention.
晚期糖基化终产物（AGEs）及其受体（RAGE）可能在肌肉减少症中发挥作用。本系统评价在观察性研究中评估了通过自体荧光（SAF）在组织（皮肤）和/或循环系统（血液、尿液）中测量的AGEs与肌肉健康结局（力量、质量、功能）及肌肉减少症之间的关联。
检索MEDLINE、Embase、Scopus和Web of Science数据库，查找报告≥30岁社区居住成年人（截至2022年3月）中AGEs与肌肉相关结局之间关联的研究。
叙述性总结纳入了14项横断面研究和1项前瞻性研究。SAF与≥30岁成年人的肌肉力量、质量和身体功能呈负相关（4项研究），与≥65岁成年人的肌肉质量（3项研究）、力量及肌肉减少症（1项研究）呈负相关。循环中的AGEs与肌肉力量和身体功能呈负相关（4项研究），并预测老年人行走障碍风险（1项前瞻性研究）及肌肉减少症（1项研究）。RAGE在肌肉健康中的作用尚无定论。
在横断面研究中，SAF和循环中的AGEs与≥30岁成年人的肌肉相关结局呈负相关。这一发现应在设计良好的关于肌肉减少症的前瞻性研究中得到证实，因为AGEs是一个潜在的可干预靶点。
